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Abstract
Purpose Statins have beneficial effects in patients after
myocardial infarction and at least part of the benefit results
from mobilization of marrow endothelial progenitors to
repopulate damaged myocardial tissues. This study exam-
ines if statins may have the same effect in mobilizing
marrow progenitors to be harvested and subsequently used
in high-dose chemotherapy with progenitor cell rescue in
multiple myeloma.
Methods From 2006 to 2012, 86 patients with multiple
myeloma were mobilized with the use of G-CSF and were
retrospectively analyzed. Patients with other malignancies
or mobilized with the use of chemotherapy or with pler-
ixafor were excluded.
Results The median age of the patients was 60 years. 72
patients had received one line of chemotherapy and 14
patients two or more lines of chemotherapy. Twenty
patients were taking statins at the time of the harvest while
66 patients were not. In the group of patients taking statins
the success rate of first leukapheresis (obtaining the target
number of 4 9 106 CD34? cells/kg) was 85 % while in
the group not taking statins this rate was 63.6 %. Despite
the comparatively small number of patients this difference
approached statistical significance (v2 = 0.07).
Conclusion This retrospective analysis of 86 patients
shows for the first time a possible benefit of statins for
peripheral blood progenitor cells mobilization in patients
with multiple myeloma. Larger studies would be required
to clarify the issue. If their effectiveness is confirmed,
statins could be a safe and cheaper addition to chemo-
therapy and plerixafor for peripheral hematopoietic stem
cell mobilization.
Keywords Statins  Autologous transplantation 
Mobilization  Multiple myeloma
Introduction
Statins are drugs that inhibit the enzyme 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase and are
extensively used in the treatment of hypercholesterolemia
to prevent cardiovascular events [1]. HMG-CoA reductase
is the first enzyme of the steroids biosynthesis and pre-
nylation pathways and catalyzes the production of meva-
lonate from HMG-CoA [2]. In subsequent enzymatic
reactions mevalonate is transformed to prenylation pre-
cursor geranyl pyrophosphate and to steroids precursor
squalene. The beneficial effects of statins in patients with
coronary artery disease and after myocardial infarction are
believed to result, at least in part, from mobilization of
marrow endothelial progenitors to repopulate damaged
myocardial tissues [3]. Ischemic injury leads to the pro-
duction of cytokines which triggers release of endothelial
progenitors from the bone marrow [4]. In addition, pro-
genitor cells expressing hematopoietic stem cell surface
markers such as CD34, CD117 and CXCR4 are concomi-
tantly released [5]. Statins promote the release of endo-
thelial progenitor cells from bone marrow following
myocardial infarction [6]. Such an effect in mobilization of
progenitors, and specifically of hematopoietic progenitors,
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would also be desirable in the setting of harvesting for
subsequent autologous transplantation for the treatment of
hematologic malignancies. The present study examines if
statins may have an effect in the mobilization of marrow
progenitors to the peripheral circulation in order to be
harvested and subsequently used in high-dose chemother-
apy with progenitor cell rescue in patients with multiple
myeloma.
Patients and methods
Medical records of patients with multiple myeloma mobi-
lized and harvested in the University Hospital of Lausanne
in order to obtain hematopoietic stem and progenitor cells
for subsequent autologous peripheral hematopoietic stem
cell transplantation were reviewed. From 2006 to June
2012, 86 patients with multiple myeloma were mobilized
with the use of G-CSF alone and were included in this
retrospective analysis. Age and sex of the patients, type and
stage of myeloma at diagnosis and previous therapies
received were recorded. Administration of concomitant
medications for cardiovascular diseases was noted. Infor-
mation regarding the number of leukapheresis sessions and
the number of mobilized CD34? cells per ll of peripheral
blood the morning of leukapheresis in each patient and
whether he or she was taking statins at the time of the
procedures were also recorded. Patients with other malig-
nancies or mobilized with the use of chemotherapy or with
plerixafor were excluded from the analysis. Comparisons
of the mean values of CD34? mobilized cells in the two
groups taking or not taking statins was done using the t test.
Associations of different prognostic parameters in the two
groups were evaluated using the v2 test. A logistic
regression analysis was performed to test the influence of
age, sex, stage, previous lines of anti-myeloma treatments,
other concomitant cardiovascular medications and statins
on the success of first leukapheresis.
Results
The median age of the patients was 60 years (range 37–72).
There were 60 men and 26 women in the entire cohort of
patients. 15.1 % of the patients had Salmon–Durie stage I
disease, 23.3 % had Salmon–Durie stage II disease and
61.6 % had stage III disease. Seventy-two patients had
received one line of chemotherapy and 14 patients had two
lines or more before mobilization. 48 patients had IgG
immunoglobulin myeloma, 22 patients had IgA myeloma
and 16 patients had light chains disease. Twenty patients
were taking statins (atorvastatin, 9 patients; 4 at 40 mg/day
and 5 at 20 mg/day, pravastatin, 5 patients; 4 at 20 mg/day
and 1 at 10 mg/day and simvastatin, 6 patients; 4 at 40
mg/day and 2 at 20 mg/day) at the time of the harvest
while 66 patients were not taking HMG-CoA reductase
inhibitors. The median age of the group taking statins was
61.5 years (range 45–72) while the median age of the
control group (patients not taking statins) was 60 years
(range 37–69). There was no statistically significant dif-
ference between the two groups in other parameters that
could affect mobilization such as age, disease stage at
Table 1 Characteristics and outcomes of the whole group of patients studied and the two groups of patients based on whether they were taking
statins at the time of leukapheresis
Total (n = 86) (%) Control (n = 66) (%) Statins (n = 20) (%) v2
Age (year, median) 60 60 61.5
Sex
Male 60 (69.8) 45 (68.2) 15 (75) p = 0.55
Female 26 (30.2) 21 (31.8) 5 (25)
Salmon–Durie stage
I 13 (15.1) 9 (13.6) 4 (20) p = 0.73
II 20 (23.3) 15 (22.7) 5 (25}
III 53 (61.6) 42 (63.6) 11 (55)
Previous lines of chemotherapy
1 72 (83.7] 55 (83.3) 17 (85) p = 0.85
C2 14 (16.3) 11 (16.7) 3 (15)
Success of 1st leukapheresis 59 (68.6) 42 (63.6) 17 (85) p = 0.07
CV treatments 37 (43} 24 (36.3) 13 (65) p = 0.02
Median CD34+ count 9l06/kg 5.2 5.0 6.3
The v2 column gives the p value of the comparison between the two groups
Control group patients not taking statins, CV cardiovascular
86 Clin Transl Oncol (2014) 16:85–90
123
diagnosis and previous therapies received (Table 1). Three
patients in the statin group (15 %) and 11 in the control
group (16.7 %) had received two or more lines of che-
motherapy before mobilization (p = 0.85). No patient in
either group has received more than four cycles of lena-
lidomide-containing regimens. Thirteen patients (65 %)
were taking additional cardiovascular medications includ-
ing anti-hypertensive, anti-arrhythmic, congestive heart
failure medications, aspirin, coumadins and heparins in the
statin group and 24 patients (36.3 %) were taking such
medications in the control group (p = 0.02).
In the group of patients taking statins the target number
of 4 9 106 CD34? cells/kg could be obtained with a single
apheresis session in 17 of 20 (85 %) patients (Table 1).
From the three remaining patients, two required a second
session to complete mobilization and one required three
sessions. In the group not taking statins, in 42 of 66 patients
(63.6 %) the target number of 4 9 106 CD34? cells/kg
was obtained with one session while the rest required more
than one session to obtain the desired number. This dif-
ference shows a trend towards statistical significance
(v2 = 3.25, p = 0.07). In multivariate logistic regression
analysis (Table 2), statin treatment and the number of
previous chemotherapy lines (one versus two or more)
were the only variables that approached statistical signifi-
cance (p = 0.06 and 0.07, respectively) while no trend for
significance was observed for the other parameters
including the age and the sex of the patients, the Salmon–
Durie stage of the disease and whether patients were
receiving treatments for cardiovascular diseases. With
additional apheresis sessions the target number of 4 9 106
CD34? cells/kg could be obtained in all patients taking
statins and in 60 of 66 patients not taking statins. Thus, the
overall failure rate was 0 and 9.1 %, respectively,
(p = 0.16). Six patients in the non-statin group could not
be mobilized and had to receive alternative treatments
without transplantation. In the 18 other patients, the
required number was obtained with two sessions in 14
patients and with three sessions in four patients. The
median number of cells harvested was 6.3 9 106 CD34?
cells/kg in the group taking statins and 5.0 9 106 CD34?
cells/kg in the control group. The mean number of cells
harvested (±95 % confidence interval) was 6.87 ±
1.46 9 106 CD34? cells/kg in the group taking statins and
6.06 ± 1.05 9 106 CD34? cells/kg in the control group
(two-tailed t test p = 0.36). The mean absolute CD34?
cell count mobilized in the peripheral blood the morning of
the first leukapheresis (±95 % confidence interval) was
100.2 ± 35.43/ll in the statin group and 84.1 ± 16/ll in
the control group (two-tailed t test p = 0.35). The duration
of statin therapy in these patients was not systematically
recorded and could not be ascertained from our retro-
spective data base.
Discussion
An effect of HMG-CoA reductase inhibitors in bone mar-
row progenitor cell mobilization has been suggested in pre-
clinical models and in the clinic and possibly contributes to
the beneficial effects of statins in myocardial infarction
patients [7, 8]. A study in pigs in which a coronary artery
was rendered stenotic to produce hibernating myocardium
showed that treatment with pravastatin for 5 weeks pro-
duced a dose-dependent increase of CD133?/c-kit? cells
in the circulation and in the diseased myocardium [7]. Both
these markers are expressed not only by endothelial but
also by hematopoietic progenitors. In a clinical study,
treatment of patients undergoing a coronary stent place-
ment with just 3 days of high-dose atorvastatin augmented
the number of circulating endothelial progenitor cells by
3.5-fold [8].
Given these data, we examined in this retrospective
study whether an effect in hematopoietic progenitor cell
mobilization could be discernible in myeloma patients
taking statins at the time of the procedure compared with
patients not taking these drugs. Indeed, we observed that
the success of the first leukapheresis increased from 63.6 %
in control patients not taking statins to 85 % in patients
taking statins. This effect approached but did not reach
statistical significance (p = 0.07). In multivariate logistic
regression analysis with the success of first leukapheresis
as the dependent variable, treatment with statins and the
number of previous lines of chemotherapy were the only
parameters that approached statistical significance while
the age and sex of the patients, the stage of myeloma and
whether or not patients were receiving other drugs for
cardiovascular diseases were not statistically significant. In
Table 2 Logistic regression analysis with the success of first leuka-
pheresis as the dependent variable and age sex stage of the disease (I
and II versus III) previous lines of chemotherapy (one versus two or
more), statin treatment and treatment with other cardiovascular drugs
as the independent variables
Variable Hazard
ratio
95 % confidence
interval
p value
Lower
limit
Upper
limit
Age 0.9794 0.9191 1.0438 0.5223
Sex 1.2433 0.4308 3.5880 0.6871
Stage 1.3878 0.5139 3.7473 0.5179
Previous
chemotherapies
0.2927 0.0766 1.1181 0.0724
Statins 3.6382 0.9067 14.5984 0.0685
Other CV treatments 0.7890 0.2746 2.2674 0.6599
CV cardiovascular
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addition, the median number of harvested cells increased in
statin-treated patients and the overall failure rate decreased
from almost 10 % in controls to 0. These effects in
mobilization become more interesting if one takes into
account that hypercholesterolemia and atherosclerotic
vascular disease, conditions for which patients in the study
were treated with statins, are risk factors for decreased
progenitor mobilization [9]. In our series population, 65 %
of patients in the statin group and 36.3 % of patients in the
control group were taking other cardiovascular
medications.
Hypercholesterolemia leads to accumulation of LDLs
(low-density lipoproteins) in the subendothelial space of
vessels and promotes atherosclerosis. Atherosclerosis is a
risk factor for impaired stem cell mobilization and, as a
result, its reversal may negate this impairment [10]. Ath-
erosclerosis in the bone marrow microvasculature inter-
feres with the local microenvironment of the perivascular
niche where hematopoietic stem cells primed for mobili-
zation reside [11]. Perivascular niche is part of the well-
vascularized areas of bone marrow and may be more
affected by vascular endothelial dysfunction characterizing
hypercholesterolemia as opposed to the endosteal niche
which is a less well-perfused area and where hematopoietic
stem cells are maintained quiescent. Alternatively, both
quiescent and primed progenitors residing in the two types
of niches may be equally affected by vascular dysfunction,
given their dynamic properties that allow them to pass from
the one state to the other [11, 12]. Monocyte and macro-
phage lineage cells constitute an important part of the
atherosclerotic lesion becoming loaded with cholesterol
and transformed to foamy cells. Monocytes are also part of
the hematopoietic stem cell niches in the bone marrow and
mediate the signal of mobilization by G-CSF [13]. As
opposed to hematopoietic stem cells, monocytes express
the receptor for G-CSF on their surface and, after ligation,
signal to down-regulate adhesion molecules that retain
adjacent stem cells in the niche [11]. Thus, dysfunction of
monocytes in hypercholesterolemia could interfere with
G-CSF-mediated mobilization.
Reversal of hypercholesterolemia may not be the only
factor promoting stem cell mobilization by statins and
other mechanisms may contribute. In fact hypercholester-
olemia per se may promote hematopoietic cell mobilization
and it is many times associated with neutrophilia in humans
[14]. A study examining stem cell mobilization after high-
dose cyclophosphamide and G-CSF treatment found that
hypercholesterolemic patients had better mobilization
results than normocholesterolemic patients [15]. As statins
interfere with cholesterol production leading to decreased
plasma cholesterol, this cholesterol-lowering effect could
be a factor that contributes to decreased mobilization. On
the other hand, statins reversal of endothelial dysfunction
would be expected to positively influence mobilization.
Despite these contradictory influences of statins on cell
mobilization, other effects stemming from decreased
plasma cholesterol and impaired biosynthesis may be sal-
utary for progenitor cells survival and readiness to be
mobilized. Cholesterol biosynthesis is involved in the
maturation process of myeloid progenitors and inhibition
by statins may influence progenitor number and ability to
interact with bone marrow microenvironment [16]. Lower
plasma cholesterol decreases the availability of this lipid
for incorporation in plasma membranes and could con-
tribute to a re-organization of membrane domains with an
effect on membrane content for growth factor receptors and
adhesion molecules. Lipid rafts, membrane domains rich in
cholesterol and sphingolipids are platforms for signaling
emanating from the surface of cells by facilitating inter-
actions of receptors and co-receptor molecules after inter-
action with ligands [17]. Interference with cholesterol
biosynthesis and availability to be incorporated to mem-
brane rafts may impede maturation of progenitors till
robust signals such as pharmacologic doses of G-CSF used
in the clinic for mobilization arrive.
The influence of statins in reversal of endothelial dys-
function accompanying atherosclerosis is mediated not
only by their effect on cholesterol metabolism but also by
cholesterol-independent actions. Nitric oxide (NO) is a
bioactive molecule with strong vasodilator properties. Its
production is increased by statins through activation of the
endothelial NO synthase (eNOS) [18]. NO promotes bone
marrow progenitors mobilization [19].
Statins have been reported to possess anti-myeloma
effects in cell culture in vitro and in initial clinical trials
and this could be an additional argument for using the
drugs in myeloma patients in preparation for autologous
transplantation [20]. In a small clinical study the addition
of lovastatin to thalidomide and dexamethasone has
improved progression-free survival and overall survival of
relapsed or refractory myeloma patients compared with
thalidomide and dexamethasone without lovastatin [20]. In
another study, myeloma patients who underwent autolo-
gous transplantation and had used statins in the peri-
transplantation period had a trend towards a higher overall
response rate (Complete Response, Very Good Partial
Response and Partial Response) compared with patients
who had not used statins during this period [21]. Although
no study has reported the use of statins as mobilizing
agents to date, it is interesting to note that in this last study
[21] the number of stem cells mobilized in patients taking a
statin in the peri-transplantation period was higher than in
patients who were not (mean 8.3 9 106 CD34? cells/kg
versus 6.5 9 106 CD34? cells/kg).
Previous therapy may interfere with the success of
hematopoietic stem cell harvest in multiple myeloma
88 Clin Transl Oncol (2014) 16:85–90
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patients. Specifically, protracted use of lenalidomide has
been shown to decrease the success of leukapheresis while
no clear effect of thalidomide or bortezomib has been
documented [22, 23]. Thus, an expert panel guideline
recommends hematopoietic progenitor harvest early in the
course of such treatment preferably within the first four
cycles [24]. The mechanism of this untoward lenalidomide
effect does not appear to be due to direct stem cell toxicity,
but may involve an increase in endogenous G-CSF con-
centrations that would lead to tachyphylaxis at the time of
exogenous G-CSF administration for mobilization [25]. In
our series no patient had received more than four cycles of
lenalidomide-containing chemotherapy at the time of
harvest.
The duration of statin treatment in our patient popula-
tion could not be accurately ascertained from our retro-
spectively examined records. Nevertheless, this duration
may not be critical for the possible mobilization effect
given that in coronary artery disease patients undergoing
coronary stent placement, progenitor cell mobilization was
observed with just 3 days of treatment [8]. A blunting of
the mobilization effect is noted with longer treatments [8,
26]. These data may also imply that a brief treatment with
statins for a few days prior to harvest in myeloma patients
could be sufficient to derive the mobilization benefit.
In conclusion, this retrospective analysis of 86 patients
discloses a numerically important difference in the success
of peripheral blood progenitors harvest in patients taking
statins with a trend towards statistical significance. This is
clearly a hypothesis-generating investigation and larger
studies would be required to clarify the issue of a possible
beneficial effect of statins in hematopoietic progenitor cell
mobilization. These studies should optimally be prospec-
tive and randomized and include sufficient patients to
show an effect. Based on the magnitude of the benefit
seen in our study, 180–200 patients could be sufficient.
Only patients not taking statins at the time of randomi-
zation or recently before would be eligible. Treatment
could be as brief as several days and an escalation period
up to the maximal recommended dose for hypercholes-
terolemia (for which extensive data on safety exist) could
precede the full dose period. A short period of overall
treatment would have the additional advantage to be
practical as it would not significantly interfere with the
timetable of the standard autologous transplantation
treatment for these patients. In addition, it would avoid
any undesirable effect associated with long-term statin
treatment such as myopathy and increased diabetes risk
[27]. A translational component to elucidate the mecha-
nisms of the possible mobilization effect would be highly
desirable. This should include an analysis of adhesion
molecules and membrane domains on mobilized progeni-
tors and the effects of statins on them. If their
effectiveness is confirmed, statins could be a safe and
cheaper addition to chemotherapy and plerixafor for
peripheral hematopoietic stem cell mobilization in multi-
ple myeloma and possibly other hematologic
malignancies.
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